Dublin, May 02, 2019 (GLOBE NEWSWIRE) -- The "Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
The report 'Smoothened Homolog - Pipeline Review, H1 2019' outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. The report covers products from therapy areas Oncology, Gastrointestinal, Immunology and Undisclosed which include indications Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Medulloblastoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Leukemias, Peritoneal Cancer, Prostate Cancer, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Cirrhosis, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Graft Versus Host Disease (GVHD), Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Neuroendocrine Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Unspecified.
Scope
- The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
- The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
- The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
- AlfaSigma SpA
- F. Hoffmann-La Roche Ltd
- Genentech Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- IMPACT Therapeutics Inc
- Mayne Pharma Group Ltd
- PellePharm Inc
- Pfizer Inc
- Sun Pharma Advanced Research Company Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pvek78
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.